Prostate and other urologic cancers
Advanced treatment options for better outcomes
Prostate cancer is the second most common cancer among American men. Fortunately, survival rates are excellent, and new less invasive surgery and advanced treatment options offer enhanced quality of life.
Prostate cancer affects one in every six men in the U.S. Roughly 90% of all prostate cancers are detected in the early stages when tumors are confined within the prostate, making the cure rate promising. Some prostate cancers are more aggressive than others. If those aggressive tumors are untreated and allowed to grow, they can spread to other parts of the body, causing the cure rate to drop dramatically.
Prostate cancer screening
Prostate cancer screening (PSA--prostate-specific antigen blood test) has a role in detecting early prostate cancers. The American Cancer Society* recommends you talk to your doctor about the risks and benefits of the screening to decide if it is appropriate for you. This discussion should take place at the following ages:
50 for men at average risk of prostate cancer and are expected to live at least 10 more years.
45 for men at high risk of developing prostate cancer. This includes African Americans and men who have a first-degree relative (father, brother, or son) diagnosed with prostate cancer at an early age (younger than age 65).
40 for men at even higher risk, or those with more than one first-degree relative who had prostate cancer at an early age.
* Other organizations have slightly different recommendations.
LG Health/Penn Medicine has a comprehensive prostate cancer program that combines clinical expertise, advanced technology, and a multidisciplinary team including board-certified urologists, radiation oncologists, medical oncologists, pathologists and nurse specialists.
Treatment options include observation, surgery, radiation therapy, clinical trials, and hormonal therapy. Treatment recommendations are made based on your health, the stage at which the cancer is detected, and quality of life considerations like urinary incontinence and sexual potency.
Open radical prostatectomy, or removal of the prostate, is one of the surgical treatment options available. Minimally invasive daVinci® robotic surgery is a less invasive approach which may mean less blood loss, a shorter hospital stay, and reduced catheterization time. Recovery time averages 2-4 weeks, compared to 6-8 weeks for an open radical prostatectomy.
Radiation therapy options include brachytherapy where radioactive seeds are implanted in the prostate; intensity modulated radiation therapy (IMRT); and image guided radiation therapy (IGRT).
Immunotherapy (PROVENGE) is a revolutionary new treatment that activates a patient’s own immune system to seek out and attack advanced prostate cancer.
Our most advanced treatment option, TomoTherapy® Hi-Art® is a form of IMRT that uses CT scans to map a precise, 360º dose of radiation to more precisely match the shape of the tumor while minimizing radiation exposure to surrounding healthy tissue. TomoTherapy® treatments are more accurate than other IMRT/IGRT methods, resulting in a more precise and safer experience for patients.
Patients can also participate in clinical trials, which offer a unique opportunity to take advantage of expanded treatment options currently being studied and developed, while advancing cancer care.
Other urologic cancers
Click on the urologic cancer below for more information: